| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,438 |
5,202 |
$178K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
4,109 |
3,793 |
$177K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
4,485 |
3,180 |
$136K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
9,414 |
7,649 |
$89K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,169 |
982 |
$46K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,800 |
1,585 |
$36K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
522 |
455 |
$23K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
727 |
633 |
$23K |
| 87428 |
|
317 |
291 |
$15K |
| 86328 |
|
367 |
312 |
$12K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,052 |
911 |
$11K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
321 |
299 |
$9K |
| 99000 |
|
491 |
441 |
$3K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
170 |
79 |
$2K |
| 95165 |
Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials |
251 |
241 |
$2K |
| 0001A |
|
40 |
39 |
$1K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
14 |
14 |
$938.25 |
| 0002A |
|
17 |
17 |
$573.60 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
51 |
49 |
$498.12 |
| G0442 |
Annual alcohol misuse screening, 5 to 15 minutes |
270 |
227 |
$442.08 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
302 |
254 |
$442.08 |
| 96130 |
|
264 |
218 |
$376.66 |
| 36410 |
|
19 |
18 |
$240.35 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
49 |
43 |
$183.19 |
| 90688 |
|
48 |
43 |
$154.07 |
| 99401 |
|
423 |
352 |
$21.00 |
| 99072 |
|
1,048 |
895 |
$10.50 |
| 1111F |
|
46 |
31 |
$0.00 |
| 36415 |
Collection of venous blood by venipuncture |
58 |
48 |
$0.00 |
| 97803 |
|
14 |
12 |
$0.00 |